ORIL’s strategy is to aggressively seek intellectual property protection on proprietary technologies where the scientific, business and legal support for such protection are soundly based. The technology is 100% owned by the Company. To date 4 patent families have been granted or are pending in national phase entry with a number of other patent applications being drafted. The Company has also filed “Composition of Matter” patent protection for its process of a physical form of ORIL007 that provides the same efficacious properties of plant-extracted ORIL007, but with superior physical characteristics for stability, formulation and materials handling.
The PCT applications and provisional patent applications listed below have been filed or are planned to be filed in the near future. Other patents underpinning the IP portfolio are being drafted or planned for the near future.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia